The gas-sensing capsule assesses the functional health of a patient’s entire gastrointestinal system and aims to provide: better diagnosis, more targeted and personalized treatment, earlier relief of symptoms and improved healthcare outcomes.
The capsule can electronically report important data by continuously detecting gases and wirelessly transmitting the data to provide insights into the location of the capsule, microbiome function and gastrointestinal health.
The ingestible capsule offers a potential diagnostic tool for many disorders of the gut from motility disorders, IBS and IBD to liver disease.
The Atmo Gas Capsule is currently an investigational device exclusively for use in clinical investigations, and is not available for sale.
Gut disorders are common and debilitating
Gut disorders are one of the most common ailments in the world affecting tens of millions of people.
These disorders include motility abnormalities, SIBO, IBS and IBD. Gases are important biomarkers of disease, dysfunction and dysbiosis.
AFFECTED
40% of global population suffer from a Functional Gastrointestinal Disorder (FGID).
UNDIAGNOSED
30% of patients remain undiagnosed and suffer from the recurrence of disorders.
SUFFERERS IN USA
IBS affects 25 to 45 million people in the USA and 2 to 5 million in Australia.
MARKET
GI disorders and disease treatment market (2013 USD).
How the Atmo Gas Capsule works
The vitamin-sized electronic “Lab-in-a-Pill” measures gaseous biomarkers at the source of production as it passes through the gastrointestinal system. This data is continuously transmitted to a pocket-sized receiver, and sent to the cloud for aggregation, analysis, and diagnosis.
The gas sensors are sealed within a special membrane that allows gas in but keeps out stomach acid and digestive juices.
The capsule aims to determine transit times derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of multi-gas, capsule tumble, and antenna reflectance.
News
-
Atmo Biosciences reaches 60 per cent recruitment target in dysmotility pivotal clinical study
October 3, 2023. Atmo Biosciences has reached 60 per cent of its recruitment target for a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in p...
-
Breakthrough Victoria announces investment in Atmo Biosciences to help people with gut disorders
September 25, 2023. Breakthrough Victoria today announced it has invested in Atmo Biosciences to support the commercialization of the company’s world-first ingestible gas-sensing capsule that can he...
-
Atmo Biosciences selected into ANDHealth+ commercialization program to help scale its products nationally and internationally
August 25, 2023. Atmo Biosciences is one of only five businesses accepted into the market-leading ANDHealth+ commercialization program, which helps digital health companies to scale their products nat...
-
Atmo Biosciences recruits first patients in dysmotility pivotal clinical study
August 10, 2023. Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced it has c...
-
Published trial results find Atmo Gas Capsule can detect changes in regional colonic fermentation in IBS patients
6 July, 2023. A Monash University clinical study published in the journal Alimentary Pharmacology & Therapeutics1 has found that Atmo Biosciences’ gas-sensing capsule can be used to provide insi...
-
Preliminary data presented at DDW suggests Atmo Gas Capsule could be used as diagnostic tool for SIBO
17 May, 2023. Preliminary results from a University of Queensland (UQ) study to assess how the Atmo Gas Capsule compares to established SIBO (small intestinal bacterial overgrowth) diagnostic methods ...
Media coverage
AUSBIZ
The tiny device revolutionising gut health diagnostics
24 September 2021
AUSTRALIAN FINANCIAL REVIEW
Gut health medtech Atmo Biosciences raises $9.6m
23 September 2021
BBC
Gas detecting pill could diagnose poor gut health
23 January 2018
“Gases produced in the gut are clinically valuable biomarkers for gastrointestinal health and dysfunction.”
Kalantar-Zadeh, K., Berean, K.J., Burgell, R.E. et al. Intestinal gases: influence on gut disorders and the role of dietary manipulations. Nat Rev Gastroenterol Hepatol 16, 733–747 (2019). https://doi.org/10.1038/s41575-019-0193-z
Medical Advisory Board
Prof. Eamonn Quigley
Houston Methodist Hospital, Weill Cornell Medical College
Prof. Peter Gibson
Monash University, The Alfred
Prof William D. Chey
University of Michigan
Prof. Satish Rao
Augusta University
Assoc. Prof. Braden Kuo
Massachusetts General Hospital, Harvard Medical School
Prof. Anthony Lembo
Cleveland Clinic
Prof. Lin Chang
University of California
Board
Malcolm Hebblewhite
CEO and Co-Founder
Kate Hill
Chair of the Board & Non-Executive Director
Dr. Chris Roberts AO
Non-Executive Director
Chris Bertrand
Non-Executive Director
Operations
Dr. Kyle Berean
VP Technology and Co-Founder
Dr. James John
VP Operations and Co-Founder
Sue Dafnias
Head of Commercial
Dr. Carl Runde
Chief Financial Officer
Dr. Adam Chrimes
Principal Engineer and Co-Founder
Matt Reeves
Manufacturing Manager
Advisory
Professor Kourosh Kalantar-zadeh
Lead Scientific Advisor
Partners
